Awan FT, Yande S, Esterberg L, Nagar SP, Goyal RK, Priyadarshini M. Economic burden in patients (pt) with CLL/SLL (CLL) who received ≥ 2 prior lines of therapy (LOT), including a Bruton tyrosine kinase inhibitor (BTKi): a SEER-Medicare analysis. Poster presented at the ASCO Quality Care Symposium 2023; October 27, 2023. Boston, MA. [abstract] JCO Oncol Pract. 2023 Nov 1; 19(11 Suppl):23-4. doi: 10.1200/OP.2023.19.11_suppl.24
Gnanasakthy A, Norcross L, Clark M, Fitzgerald K. A review of patient-reported outcome considerations in oncologic drug advisory committee meetings (2016-2021). JCO Oncol Pract. 2023 May;19(5):e745-62. doi: 10.1200/OP.22.00774
Young L, Dong O, Wiltshire T, Kypzyk K, Guenzel N. MC4R polymorphism associated with antipsychotic-associated weight gain. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 17, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:121. doi: 10.1159/000480052
Dong OM, Suzuki O, Howard R, Jamieson K, Pointer M, Kohlmeier T, Wiltshire T. Using targeted next-generation sequencing as a cost-efficient method to characterize the genetics of salt sensitivity. Poster presented at the 11th Congress of the International Society of Nutrigenetics and Nutrigenomics Annual Meeting; September 18, 2017. Los Angeles, CA. [abstract] J Nutrigenet Nutrigenomics. 2017; 10:100. doi: 10.1159/000480052
Dalley C, Basarir H, Wright JG, Fernando M, Pearson D, Ward SE, Thokula P, Krishnankutty A, Wilson G, Dalton A, Talley P, Barnett D, Hughes D, Porter NR, Reilly JT, Snowden JA. Specialist integrated haematological malignancy diagnostic services: an Activity Based Cost (ABC) analysis of a networked laboratory service model. J Clin Pathol. 2015 Apr;68(4):292-300. doi: 10.1136/jclinpath-2014-202624